Patent ID: 8859516

Claim:
A method of treating a human having advanced cancer with liver involvement, comprising administering to the human 0.1, 0.2, 0.4, or 0.7 mg/kg ALN-VSP02 via 15 minute intravenous (IV) infusion once every 2 weeks for eight weeks, wherein the ALN-VSP02 provides a mean KSP siRNA AUC 0-last from 10 to 800 μg*min/mL, a mean KSP siRNA C max from 0.4 to 13 μg/mL, a mean VEGF siRNA AUC 0-last from 10 to 800 μg*min/mL and a mean VEGF siRNA C max from 0.4 to 13 μg/mL.